Nyxoah Launches New Therapy for Marking a Major Step Forward in Patient-Centric OSA Care
Published: 18 Dec 2025
Author: Precedence Research
Nyxoah SA, a medical technology innovator focused on advanced treatments for Obstructive Sleep Apnea (OSA), has announced the commercial launch of its Genio neurostimulation system in the Netherlands. The first successful Genio implantations at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen demonstrated significant growth of Nyxoah's presence in Europe. Through this launch, Dutch patients who cannot tolerate continuous positive airway pressure (CPAP) therapy will now have a new, clinically proven alternative. This is expected to restore restful sleep and improve long-term health outcomes.
Bilateral hypoglossal nerve stimulation offers a reliable and patient-friendly approach to treating OSA. The adoption of Genio in major Dutch hospitals shows that confidence in bilateral hypoglossal nerve stimulation as a treatment for OSA is gradually growing. Genio is a leadless, battery free implantable neurostimulation system, unlike traditional systems that rely on an external activation chip to deliver power. This design simplifies the implantation process and eliminates the need for battery replacement surgeries. These features are major advantages, making it appealing for long-term use by both patients and healthcare providers.
The scientific and clinical benefits of the Genio system were recognized by clinicians at OLVG West in Amsterdam. The therapy stimulates both branches of the hypoglossal nerve, providing effective and balanced airway control during sleep. Its upgradeable external activation feature ensures that patients can benefit from future technological advancements without needing additional invasive procedures. This also enhances the long-term value of Genio. Additionally, the accumulated knowledge positions Genio as a globally relevant therapy, aligning with Nyxoah's goal to transform the quality of care for sleep-disordered breathing worldwide.
Executive Statement
Olivier Taelman, Chief Executive Officer of Nyxoah, commented on the launch
“The commercial introduction of Genio in the Netherlands marks another important step in our European expansion and reflects increasing confidence in our bilateral, externally powered therapy. We are proud to collaborate with leading Dutch centers to provide patients with an effective, patient-centric alternative to CPAP. These first implants further validate Genio’s potential as a durable, long-term solution for OSA.”